Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	190.91	36.56	8.78	12.41	-	-
Revenue Growth (YoY)	2333.81%	316.34%	-29.22%	-	-	-
Gross Profit	190.91	36.56	8.78	12.41	-	-
Selling, General & Admin	53.23	48.79	41.32	38.92	31.9	20.85
Research & Development	99.44	89.13	82.23	77.84	54.17	32.2
Operating Expenses	152.67	137.93	123.55	116.76	86.07	53.04
Operating Income	38.24	-101.37	-114.77	-104.36	-86.07	-53.04
Interest & Investment Income	13.1	12.64	9.91	3.12	0.12	0.7
Other Non Operating Income (Expenses)	0.21	-0.25	0.17	0.17	0.14	0.1
Pretax Income	51.55	-88.98	-104.7	-101.07	-85.81	-52.24
Net Income	50.27	-88.98	-104.7	-101.07	-85.81	-52.24
Net Income to Common	50.27	-88.98	-104.7	-101.07	-85.81	-52.24
Shares Outstanding (Basic)	57	54	44	39	37	33
Shares Outstanding (Diluted)	57	54	44	39	37	33
Shares Change (YoY)	27.55%	22.76%	13.11%	5.87%	9.71%	86.34%
EPS (Basic)	0.88	-1.65	-2.38	-2.60	-2.34	-1.56
EPS (Diluted)	0.88	-1.65	-2.38	-2.60	-2.34	-1.56
Free Cash Flow	69.2	-87.05	-82.68	-35.83	-68.11	-43.27
Free Cash Flow Per Share	1.21	-1.61	-1.88	-0.92	-1.85	-1.29
Gross Margin	100.00%	100.00%	100.00%	100.00%	-	-
Operating Margin	20.03%	-277.31%	-1307.21%	-841.24%	-	-
Profit Margin	26.33%	-243.42%	-1192.47%	-814.73%	-	-
Free Cash Flow Margin	36.25%	-238.15%	-941.72%	-288.82%	-	-
EBITDA	40.33	-99.2	-112.3	-102.81	-85.09	-52.16
EBITDA Margin	21.13%	-271.36%	-	-	-	-
D&A For EBITDA	2.09	2.18	2.47	1.55	0.97	0.89
EBIT	38.24	-101.37	-114.77	-104.36	-86.07	-53.04
EBIT Margin	20.03%	-277.31%	-	-	-	-

Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q